» Articles » PMID: 16467083

Homeodomain-interacting Protein Kinase-2 Restrains Cytosolic Phospholipase A2-dependent Prostaglandin E2 Generation in Human Colorectal Cancer Cells

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2006 Feb 10
PMID 16467083
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Homeodomain-interacting protein kinase-2 (HIPK2), a corepressor for homeodomain transcription factors, is a multifunctional kinase whose role in tumor cell survival is not completely clarified. We addressed whether HIPK2 restrains colon tumorigenesis by turning off cytosolic phospholipase A2 (cPLA2)-dependent prostaglandin E2 (PGE2) generation in the light of overwhelming evidence suggesting the contribution of this prostanoid in a variety of cancers.

Experimental Design: In the human colorectal cancer cell line, RKO, we studied the effect of RNA interference for HIPK2 (HIPK2i) on prostanoid biosynthesis, both in the absence and in the presence of the cPLA2 inhibitor arachidonyl trifluoromethyl ketone. We evaluated the role of HIPK2 in the cPLA2 gene regulation by reverse transcriptase-PCR, transcriptional activity, and chromatin immunoprecipitation analyses. The involvement of HIPK2 in tumorigenicity in vivo was studied by tumor growth of HIPK2i cells in nude mice. We compared the gene expression of HIPK2 and cPLA2 in human colorectal cancer specimens by reverse transcriptase-PCR.

Results: HIPK2 silencing was associated with rousing PGE2 biosynthesis that was profoundly suppressed by the cPLA2 inhibitor. HIPK2 overexpression, along with histone deacetylase-1, inhibited the cPLA2-luc promoter that is strongly acetylated in HIPK2i cells. The tumors derived from HIPK2i cells injected in nude mice showed noticeably increased growth compared with parental cells. HIPK2 mRNA levels were significantly higher in colorectal cancers of patients with familial adenomatous polyposis, which showed undetectable cPLA2 levels compared with sporadic colorectal cancer expressing cPLA2.

Conclusions: Our findings reveal the novel mechanism of HIPK2 to restrain progression of human colon tumorigenesis, at least in part, by turning off cPLA2-dependent PGE2 generation.

Citing Articles

HIPK2 in Colon Cancer: A Potential Biomarker for Tumor Progression and Response to Therapies.

Verdina A, Garufi A, DOrazi V, DOrazi G Int J Mol Sci. 2024; 25(14).

PMID: 39062921 PMC: 11277226. DOI: 10.3390/ijms25147678.


WIP1 is a novel specific target for growth hormone action.

Apaydin T, Zonis S, Zhou C, Valencia C, Barrett R, Strous G iScience. 2023; 26(11):108117.

PMID: 37876819 PMC: 10590974. DOI: 10.1016/j.isci.2023.108117.


The Sweet Side of HIPK2.

Garufi A, DOrazi V, Pistritto G, Cirone M, DOrazi G Cancers (Basel). 2023; 15(10).

PMID: 37345014 PMC: 10216817. DOI: 10.3390/cancers15102678.


HIPK2 in Angiogenesis: A Promising Biomarker in Cancer Progression and in Angiogenic Diseases.

Garufi A, DOrazi V, Pistritto G, Cirone M, DOrazi G Cancers (Basel). 2023; 15(5).

PMID: 36900356 PMC: 10000595. DOI: 10.3390/cancers15051566.


Key radioresistance regulation models and marker genes identified by integrated transcriptome analysis in nasopharyngeal carcinoma.

Sun Z, Wang X, Wang J, Wang J, Liu X, Huang R Cancer Med. 2021; 10(20):7404-7417.

PMID: 34432380 PMC: 8525106. DOI: 10.1002/cam4.4228.